联合检测ANA、ENA及抗ds-DNA抗体对监控SLE的价值

The combined assay of serum ANA, ENA and anti-ds-DNA antibody in SLE :A retrospective study

应用间接免疫荧光法、免疫印迹法及金标渗滤法分别检测２３例活动期和３４例非活动期系统性红斑狼疮（ＳＬＥ）患者血清中的抗核抗体（ＡＮＡ）、ＥＮＡ多肽抗体谱及抗ｄｓ－ＤＮＡ抗体。结果显示：活动期与非活动期ＳＬＥ患者血清中的ＡＮＡ、ＥＮＡ抗体阳性率差异无显著性（Ｐ＞０．０５），活动期ＳＬＥ患者血清中的ＡＮＡ抗体滴度、抗ｄｓ－ＤＮＡ阳性率和滴度均明显高于非活动期，两者之间差异有显著性（Ｐ＜０．０５）。抗核抗体、ＥＮＡ及抗ｄｓ－ＤＮＡ抗体的联合检测对ＳＬＥ的诊断分型、治疗预后均有重要的临床价值。

Using indirect immunofluroescence, immunoblotting and auriclabelling diacolation to assay serum ANA, ENA and anti-ds-DNA antibody in 23 patients with SLE at active stage and in 34 at non-active stage respectively, results showed that the positive rate of serum ANA and ENA antibody in SLE did not differ (P>0.05) with respect to the active and non-active stages. While the titer of serum ANA, and the popsitive rate and titer of serum anti-ds-DNA antibody at active stage were statistically different (P<0.05), compared to that at non-active stage. It was concluded that the combined assay of ANA, ENA and anti-ds-DNA is of great clinical importance to the diagnosis, treatment and prognosis of SLE.